Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
2359.HK
Strong BuyPremium GrowerFLAGWuXi AppTec Co., Ltd. · Healthcare · China · $75.0B · Avg Vol: $168M/d
WuXi AppTec is a leading global pharmaceutical contract research and manufacturing organisation with a strong quality score (Q81), net insider buying and a substantial buyback covering 3.86% of shares outstanding. Against that sits a specific, nameable policy risk: proposed US legislation naming the company and restricting federal contracting with it, which has already caused Western clients to diversify. That legislative overhang is cited and unresolved, so it withholds a screen-pass without justifying removal.
COMPANY DESCRIPTION
WuXi AppTec Co., Ltd. is a global contract research, development, and manufacturing organization (CRDMO), providing a broad range of integrated services for pharmaceutical, biotechnology, and medical device industries. Its competitive moat includes a comprehensive, end-to-end service offering from discovery to commercial manufacturing, strong scientific expertise, and cost-effective operations, making it a critical partner for global life science companies. WuXi AppTec is a leading global CRDMO, positioned at the forefront of pharmaceutical innovation, benefiting from increasing R&D outsourcing trends and a scalable operational model.
FINANCIAL SUMMARY (HKD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.8B | 46.1B | 47.2B | 46.0B | 53.2B | 18.7% | 60.3B | 70.5B | 84.2B | 25.8% |
| EPS (HKD) | 2.05 | 20.44 | 22.27 | 21.73 | 45.86 | 117.5% | 8.56 | 67.91 | 79.06 | 31.3% |
| Shares | 3.0B | 510.5M | 510.5M | 510.5M | 510.5M | -82.7% | 531.3M | — | — | — |
| Debt | 5.0B | 6.9B | 6.7B | 5.9B | 9.9B | 18.4% | 17.7B | — | — | — |
| Equity | 45.1B | 54.6B | 64.5B | 68.7B | 93.3B | 20.0% | — | — | — | — |
| Op CF | 5.4B | 12.4B | 15.7B | 14.5B | 20.1B | 39.1% | 22.8B | — | — | — |
| Inv CF | -5.7B | -11.3B | -8.9B | -6.5B | -2.3B | — | — | — | — | — |
| Fin CF | -2.0B | -1.5B | -4.6B | -4.5B | 1.3B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 2359.HK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 2359.HK | WuXi AppTec Co., Ltd.(you) | $75.0B | 92 | Strong Buy |
| LH | Labcorp Holdings Inc. | $27.2B | 85 | Strong Buy |
| A | Agilent Technologies, Inc. | $43.4B | 75 | Buy |
| DGX | Quest Diagnostics Incorporated | $26.8B | 82 | Strong Buy |
| IQV | IQVIA Holdings Inc. | $43.1B | 73 | Buy |
| ILMN | Illumina, Inc. | $32.6B | 76 | Buy |
| ERF.PA | Eurofins Scientific SE | $14.5B | 85 | Strong Buy |
| MEDP | Medpace Holdings, Inc. | $16.8B | 80 | Strong Buy |
| WAT | Waters Corporation | $40.7B | 61 | Hold |
| LONN.SW | Lonza Group AG | $50.4B | 56 | Hold |
Peer medians: ROE 2.8% · P/E 24.4x · Gross margin 52.6%